NSAIDS Flashcards

1
Q

what are 5 cardinal signs of inflammation?

A
  1. redness
  2. heat
  3. swelling
  4. pain
  5. loss of fxn
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What causes the 5 cardinal signs of inflammation?

A

vasodilation, edema, & nociceptive stimulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the uses of NSAIDS?

A
  1. prevent or reduce inflammation: block formation of inflammatory EICOSANOIDS (prostaglandins, thromboxane, leukotrienes)
  2. reduce fever (anti-pyretic): PGE”2” (prostaglandin E2) is an endogenous pyrogen (increases body temp by resetting set pt in hypothalamus)
  3. analgesic (central &/or peripheral effects)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Why do steroids cause immunosuppression while NSAIDS do not?

A

Glucocorticoids inhibit arachidonic acid production which in turn reduces leukotrienes (leading to immune suppression), but NSAIDs block PGH”2” synthase (cyclooxygenase - COX-1 or COX-2) which converts the arachidonic acid into prostaglandin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How do NSAIDS act as analgesics?

A

-they reduce PERIPHERAL inflammation which may lead to decreased pain sensation if the peripheral pain was due to swelling/press (same as corticosteroids)
- reduce prostaglandins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How do prostaglandins contribute to pain?

A

prostaglandin synergy w/ bradykinin (BK) & histamine (HT): PG can increase afferent neuron firing due to BK & HT-mediated stimulation of peripheral nociceptors
- hyperalgesia (increase effect of painful stimuli)
- allodynia (normally non-painful stimuli become painful)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How do NSAIDS contribute to central analgesia (like acetaminophen (Tylenol))?

A
  • both cyclo-oxygenase isoforms (COX-1 & -2) are present in brain & spinal tissue (produce prostaglandins in neural tissues)
  • result of central PGE formation:
    > sensitizes central nociceptors (“wind-up”)
    > lowers spinal depolarization threshold
    (so not a lot of analgesic activity on its own but lowers pain perceived by animal)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

why are NSAIDS one of the most commonly used classes of vet drugs?

A

efficacious, relatively safe, potential for profit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Why are there lots of adverse effects of NSAIDS reported to regulatory authorities?

A
  • 10% of total adverse drug events reported
  • lots of usage & used in riskier situations (geriatrics, perioperative, etc.)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What kinds of adverse drug events (ADE) are reported for NSAIDS?

A
  1. GI (~60% of ADE): vomiting, diarrhea, ulcers, melena
    - prostaglandins promote gastric mucus & bicarbonate (HCO3) secretion, increase mucosal blood flow
    - direct GI irritation (aspirin, meloxicam tablets)
  2. renal (~20% of ADE)
    - prostaglandins help maintain glomerular filtration
    - NSAIDS potentially decrease glomerular filtration rate (or just in hypovolemic animals?)
    - renal papillary necrosis/idiosyncratic toxicity?
    GI & RENAL ADEs ARE DOSE-DEPENDENT IN MOST CASES
  3. hepatic (~15% of ADE)
    - idiosyncratic hepatic necrosis/ toxicity (carprofen/bute)
    - increased liver enzymes - change to bile acids?
    - Fe most susceptible, but cant predict individual toxicity!
    HEPATIC ADE ARE STILL PROBABLY DOSE-DEPENDENT BUT DOSE-INDEPENDENT DO OCCUR
  4. hematologic (~1%)
    - prolonged bleeding times w/ aspirin & ketoprofen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the difference btwn COX-1 & COX2?

A

COX-1
- constitutive (produced constantly)
- present under normal conditions in many cells (platelets & endothelium, mucosal cells (GI), renal tubule cells, neural tissue)
- produce “cytoprotective” prostaglandins (vasodilation, mucous, etc.)
COX-2
- inducible (expressed in response to inflammatory mediators)
- often formed @ sites of inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What does COX-2 SELECTIVE mean?

A

drugs that inhibit COX-2 (but not COX-1) AT LABEL DOSE
aka COX-1 SPARING & COX-2 SPECIFIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What does COX-2 PREFERENTIAL mean?

A

drugs that inhibit COX-2 @ lower drug concentrations than COX-1, but there is some COX-1 inhibition @ label dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What does COX-NONSPECIFIC mean?

A

both COX-1 & COX-2 are inhibited @ label doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How is the category of COX inhibition determined?

A

IC ratios
- IC”50”: the drug concentration @ which 50% of enzyme activity is inhibited
- LOWER IC # means INCREASED drug potency
- so, high COX-1 IC”50” # means LESS inhibition by NSAID (COX-1 is “spared”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the problems with the IC ratio method?

A
  1. which IC ratio is most physiologically relevant: IC”50”, IC”95”? (IC “slopes” are not even for COX-1 & COX-2)
  2. experimental conditions are not uniform
    - isolated enzyme assays, intact cells, whole blood
    - difference btwn labs
  3. spp differences in IC values
    - cant extrapolate from 1 sp to another
  4. chirality
    - pharmacodynamic differences btwn R- & S- enantiomers
    - most chiral NSAIDS are racemic mixtures (ex: ketoprofen, carprofen)
    - some spp can convert enantiomers, some cant
    HARD TO COMPARE IC RATIOS BTWN NSAIDS OR SPP!
    - this theory is overly-simplistic & wrong
    - more & more COX-2 specificity isnt really beneficial (better than the old drugs but that’s about it!)
17
Q

New info on differences btwn COX-2 & COX-3?

A

COX-2
- constitutive in some tissues (kidney, brain, spinal cord)
- expressed near gastric ulcers (accelerates healing)
COX-3
- derivative of COX-1
- found in brain
- unknown fxn, but is inhibited by older NSAIDs that “seem to work” (ex: acetaminophen)

18
Q

What is COX inhibition data useful for?

A
  • determining drug potency, dose regimens, etc.
  • HOWEVER, cannot make direct comparisons of NSAID safety or efficacy based solely on PK/PD data! (yet this data has been used in marketing!)
  • PROOF of safety & efficacy ONLY comes from clinical trials, not IN VITRO data
19
Q

What are the general pharmacokinetic properties of NSAIDs?

A
  • generally good bioavailability
  • primarily eliminated by hepatic metabolism
  • highly protein bound (leading to low V”D”) -> present @ sites of peripheral inflammation
  • usually weak acids, can be ion-trapped in cells
  • BUT: kinetics are highly variable btwn spp
    > Fe have poor glucuronidation (low clearance, long half-life - most of the time)
    > sig differences among Ru
20
Q

What are the pharmacokinetic properties of COXIB-specific drugs?

A
  • varying degrees of COX-2 selectivity
  • generally v lipophilic
  • hepatic metabolism
  • VIOXX (rofecoxib) recall: increased risk of cardiovascular events (heart failure, stroke) (no evidence of this found in Ca or Fe)
21
Q

What is a washout period?

A

time period when switching btwn 2 drugs (allows 1st drug to be eliminated, increasing margin of safety when 2nd drug is administered)

22
Q

When are washout periods v important?

A

for anti-inflammatory drugs (esp going from steroids/aspirin to NSAIDs)
- Remember: diff enzyme targets, but same pathway!

23
Q

Is it a good idea to use a “washout period” when switching btwn NSAIDs?

A

ALMOST CERTAINLY YES

24
Q

How long of a washout period should you use?

A

we dont know what the correct washout period is, but should use 1 and it should be more than 1 or 2 days (3-10 days)
- warn O of risks!!